Reproductive Medicine

Renji Hospital affiliated with Shanghai Jiao Tong University School of Medicine was founded in 1844 and is a comprehensive Grade III-A tertiary hospital integrating medical care, education, and research. In 1992, it established the Shanghai Human Sperm Bank, and in 2001, it established the Reproductive Medicine Center. It currently provides the full range of diagnostic and therapeutic technologies and programs related to infertility, eugenics and healthy childbearing, and fertility preservation and restoration, with annual outpatient visits exceeding 400,000, nearly 10,000 IVF cycles, and a clinical pregnancy rate that consistently ranks first in Shanghai and is at a leading level in China. For 4 consecutive years, it has been included among the national top 10 in the specialty comprehensive rankings of the Fudan version of the China Hospital Rankings (the only reproductive center in Shanghai to be included), and in 2022, it ranked second nationwide in the National Hospital Internet Influence Index Rankings. The center has now established a comprehensive disciplinary platform, took the lead in establishing the Shanghai Jiao Tong University Specialized Center for the Diagnosis and Treatment of Infertility in 2009, and in 2010, the Shanghai Municipal Commission of Health and Family Planning approved the establishment of the Shanghai Center for Reproductive and Eugenics Technologies. In 2012, the Shanghai Municipal Commission of Science and Technology approved the establishment of the Shanghai Key Laboratory of Assisted Reproduction and Eugenics, in 2013, the Shanghai Sub-center of the National Engineering Research Center for Assisted Reproduction and Eugenics was established, and in 2014, the Shanghai Municipal Commission of Health and Family Planning approved the establishment of the Shanghai Human Assisted Reproductive Technology Training Base, which undertakes the training of newly appointed personnel at reproductive centers throughout Shanghai. In 2018, the Shanghai Human Assisted Reproductive Technology Quality Control Center was placed under the Renji Reproductive Medicine Center. In January 2019, it became the first center in China to pass the DNV GL&RTAC international accreditation specific to assisted reproduction, providing domestic and international patients with safer and higher-quality reproductive medical services. In 2021, it successfully received approval for academic platforms including the “Shanghai Center for Fertility Preservation and Restoration”, and launched nationwide for the first time the MyBaby blockchain embryo visualization application. In 2023, it was recognized as the Shanghai Top-Priority Research Center and a Shanghai Key Discipline in Public Health, and the development of its disciplines entered a new stage. Over the past 5 years, it has undertaken more than 70 research projects, including the National Key R&D Program of the Ministry of Science and Technology (principal investigator), key projects of the National Natural Science Foundation of China, and key international cooperation projects, and has published more than 300 SCI papers in leading international journals such as the “New England Journal of Medicine”(NEJM), “The Lancet”(Lancet), “Journal of the American Medical Association”(JAMA), and “Proceedings of the National Academy of Sciences”(PNAS). As the first completing institution, it has received honors including the First Prize of the Chinese Medical Science and Technology Award and the First Prize of the Shanghai Medical Science and Technology Award. Renji Reproductive Medicine will always uphold the philosophy of “compassionate hearts and healing hands, benefiting the world and bringing new life”, continuously improve the quality of medical services, strengthen discipline and talent-team development, and strive to build a world-class leading brand of excellence in reproductive medicine!